PharmaLectures.com

Courses › Pharma export and key account management › Partnering with a European wholesaler or licence holder: named-patient and early access

Partnering with a European wholesaler or licence holder: named-patient and early access

Choose a European partner who passes inspection before your batch sits in quarantine.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • BD, managementwho it is written for

Why this training matters

Your European wholesaler fails a Good Distribution Practice inspection, and the batch meant for named-patient supply goes into quarantine. Doctors keep asking for treatment that cannot ship. Your team spends weeks answering the national authority, and the launch slips.

What changes after this course

Your business development team checks a partner's Good Distribution Practice standing before the agreement is signed. They write the quality duties into the contract. You hold a certificate per learner and the training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

In the partner meeting, you know which questions to ask a European wholesaler before anyone talks price. You check its wholesale distribution authorisation, read its Good Distribution Practice audit trail, and spot the gap while the draft can still change. The agreement names who answers for storage, transport and recalls.

Your regulatory affairs team files the right request the first time. They separate compassionate use under Article 83 of Regulation (EC) No 726/2004 from named-patient supply under Article 5 of Directive 2001/83/EC. They adjust each patient request to the Member State without waiting for outside counsel. When an authority asks about one patient, the answer is already in the file.

Eligibility criteria stop being a debate. Your team writes them in plain terms that a hospital doctor can apply and a national competent authority can check. Doctors know who qualifies, and the authority sees the data it needs. Fewer requests come back to your desk asking whether a patient fits.

Supply chain and quality managers close the gap between your quality system and your partner's. They work out which parts of the Falsified Medicines Directive, 2011/62/EU, touch your early access supply, and they write the quality agreement to match. They set indicators and a reporting rhythm that fits the partner and the contract. A missed target meets a response written into the contract, not a surprise at inspection.

Who needs this training

  • Business Development Manager

    You sit in the partner meeting with a draft agreement open and a European wholesaler across the table. You need to know, before signing, whether its Good Distribution Practice standing will hold up when the authority asks.

  • Head of Regulatory Affairs

    A named-patient request comes back from a national authority with questions. Your team cannot tell whether the gap sits in the form, the route or the Member State rule. You want that settled before filing.

  • Supply Chain Director

    A recall notice arrives for a batch already at a hospital pharmacy in another country. You need the partner's records and the agreed steps to be ready, not buried in an email chain.

  • Quality Assurance Manager

    An inspector asks how you oversee your European wholesaler. You want to answer from a signed quality agreement and a set of partner reports, not from memory.

Roles: Owner, CEO and board, Business development and export sales

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Decide whether a request is compassionate use under Article 83 or named-patient supply under Article 5 of Directive 2001/83/EC.
  2. Check a European wholesaler's distribution authorisation and Good Distribution Practice audit history before signing an agreement.
  3. Run a partner audit that covers storage, transport and temperature records and ends with a written list of gaps.
  4. Draft patient eligibility criteria that a hospital doctor can apply and a national competent authority can review.
  5. Identify which Falsified Medicines Directive requirements apply to your early access supply chain and which do not.
  6. Set key performance indicators for your partner and write the response to a missed target into the contract.

What the company gets

  • Your business development team signs distribution agreements that state who answers for storage, transport and recalls.
  • Your early access requests reach national competent authorities with the paperwork they expect, which cuts the back-and-forth that holds up supply.
  • Your supply stays out of quarantine for partner gaps that an audit before signing would have found.
  • Your quality assurance managers answer inspector questions about partner oversight from a written agreement and regular reports.
  • Each learner holds a certificate, and you hold a training record for each person.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing1 h
Business development and export salesBriefing1 h

Course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Separate compassionate use from named-patient supply in your pipeline

    • Why one doctor's request for one patient follows a different route than a program for a group.
    • How to tell, in a partner meeting, which route your early access plan really takes.
    • The line between a group program and an individual request under Article 5 of Directive 2001/83/EC.
  2. 2Audit your European wholesaler against Good Distribution Practice

    • What a wholesale distribution authorisation and a Responsible Person tell you before you sign.
    • How to run an audit visit that checks storage, transport and temperature records, not only certificates.
    • What to do when the audit finds a gap and the partner asks you to sign anyway.
  3. 3Plan your program around Article 83 of Regulation (EC) No 726/2004

    • How to read the Article 83 guideline the way the Committee for Medicinal Products for Human Use does.
    • The national rules that decide whether your program needs approval in each Member State.
    • When to answer an authority query yourself and when to hand it to your partner.
  4. 4Draft patient eligibility criteria your early access program can defend

    • How to write eligibility criteria that a hospital doctor can apply without calling you.
    • The data a national authority looks for before it lets your program start.
    • When to narrow the patient group so the review moves faster, and when not to.
  5. 5Align partner quality management with the Falsified Medicines Directive

    • How to check which parts of the Falsified Medicines Directive apply to your early access supply and which do not.
    • The quality agreement clauses that make your partner answer for each batch it handles.
    • How to follow one batch from your site to the hospital pharmacy when a recall call comes.
  6. 6Set key performance indicators for partner regulatory compliance

    • The few indicators that show a partner drifting from Good Distribution Practice before an inspector does.
    • How to ask for regular partner reports your team can read in minutes.
    • What to do when a partner misses a target midway through the contract.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for BD, management. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 54 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team